Fri, Dec 19, 2014, 3:31 PM EST - U.S. Markets close in 29 mins.

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • accugrowth accugrowth Feb 23, 2013 9:58 PM Flag

    New Premacure ROP Article

    The following is a strong statement from Premacure. Enjoy.

    Abstract
    Retinopathy of prematurity is a potentially blinding disease starting with impaired retinal vessel growth in the neonatal period. Weeks to months later, peripheral retinal hypoxia induces pathologic neovascularization that may lead to retinal detachment and blindness. Current treatment strategies target late stage disease and it would be advantageous if retinopathy of prematurity could be prevented. Poor general growth after very preterm birth is a universal problem associated with increased risk of retinopathy. Loss of the maternal-fetal interaction results not only in loss of nutrients but also of other factors provided in utero. The importance of nutrition and factors such as insulin-like growth factor-1 and ω-3 long chain fatty acids for proper retinal vascularization has been defined in animal studies. Increasing evidence of the applicability of these findings to human infants is accumulating. This review focuses on factors essential for neonatal growth and possible strategies to improve growth and prevent retinopathy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The WINROP algorithm and other innovations in the screening for retinopathy of prematurity.

      González Viejo I, Ferrer Novella C, Pueyo Royo V.

      The WINROP algorithm gets further support in the following spanish language abstract. The full version will be available for free in English soon.

      Arch Soc Esp Oftalmol. 2013 Feb;88(2):43-44

    • by accugrowth•Feb 23, 2013 9:58 PMFlag
      .

      The following is a strong statement from Premacure. Enjoy.

      Abstract
      Retinopathy of prematurity is a potentially blinding disease starting with impaired retinal vessel growth in the neonatal period. Weeks to months later, peripheral retinal hypoxia induces pathologic neovascularization that may lead to retinal detachment and blindness. Current treatment strategies target late stage disease and it would be advantageous if retinopathy of prematurity could be prevented. Poor general growth after very preterm birth is a universal problem associated with increased risk of retinopathy. Loss of the maternal-fetal interaction results not only in loss of nutrients but also of other factors provided in utero. The importance of nutrition and factors such as insulin-like growth factor-1 and ω-3 long chain fatty acids for proper retinal vascularization has been defined in animal studies. Increasing evidence of the applicability of these findings to human infants is accumulating. This review focuses on factors essential for neonatal growth and possible strategies to improve growth and prevent retinopathy.

    • anyone who wants to make it in 2018 can

      • 2 Replies to eastofhgwy1
      • Sorry, East of Highway, Premacure has the Orphan Drug patent for PremiPlex well beyond 2018.

        CEO Lewis said he would keep investors updated on the negotiations with Ipsen. The annual report and the Q4 report are two opportunities to do so. I have low expectations.

        In any case, the 2013 Q1 report is also going to be due soon, since INSM is taking an unnecessary long time to close the books on 2012. I wonder why? Could it have something to do with paying off the old management team to leave? Or, is INSM in trouble for diluting shares in Q4 when there is obviously zero reason for them to have done so??

        Liking the science does not mean I like the investment at this price. By the way, there is another recent article in PubMed about how naked IGF-1 is more effective than iPlex for short stature. That market does not seem promising for INSM after 2018. The article does begin to explore infusion of iPlex for diabetes via an IV instead of a bolus injection. The number of subjects and days on treatment is very short though. Long term studies will need to be funded. But, by who?

      • Only a few billion dollars to be made before 2018. Must suck to be you Terry.

        Sentiment: Buy

 
INSM
16.39+0.34(+2.12%)3:30 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.